Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 520 articles:
HTML format



Single Articles


    July 2021
  1. WU CE, Chang CF, Huang CY, Yang CT, et al
    Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
    BMC Cancer. 2021;21:859.
    PubMed     Abstract available


  2. TANG Y, Zhang R, Li Y, Xu S, et al
    Genetic polymorphisms and haplotypes of ERCC1 and ERCC2 associated with quality of life, depression, and anxiety status among patients with lung cancer.
    BMC Cancer. 2021;21:842.
    PubMed     Abstract available


  3. LUO H, Zhang Y, Qin G, Jiang B, et al
    LncRNA MCM3AP-AS1 sponges miR-148a to enhance cell invasion and migration in small cell lung cancer.
    BMC Cancer. 2021;21:820.
    PubMed     Abstract available


  4. HUNG A, Lee KM, Lynch JA, Li Y, et al
    Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer.
    BMC Cancer. 2021;21:824.
    PubMed     Abstract available


  5. SHEN H, Deng G, Chen Q, Qian J, et al
    The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
    BMC Cancer. 2021;21:825.
    PubMed     Abstract available


  6. CHAU J, Yadav M, Liu B, Furqan M, et al
    Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
    BMC Cancer. 2021;21:808.
    PubMed     Abstract available


  7. PARK K, Kim JS, Kim JH, Kim YC, et al
    An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2021;21:802.
    PubMed     Abstract available


  8. PASCOE J, Jackson A, Gaskell C, Gaunt C, et al
    Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).
    BMC Cancer. 2021;21:800.
    PubMed     Abstract available


  9. LIU T, Luo H, Zhang J, Hu X, et al
    Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer.
    BMC Cancer. 2021;21:783.
    PubMed     Abstract available


    June 2021
  10. CHRISTOPOULOS P, Bozorgmehr F, Bruckner L, Chung I, et al
    Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
    BMC Cancer. 2021;21:743.
    PubMed     Abstract available


  11. RUSMAULLY J, Tvardik N, Martin D, Billmann R, et al
    Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study).
    BMC Cancer. 2021;21:711.
    PubMed     Abstract available


  12. ZENG H, Yang Z, Li J, Wen Y, et al
    Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones.
    BMC Cancer. 2021;21:690.
    PubMed     Abstract available


  13. ZHOU H, Li J, Chen Z, Chen Y, et al
    Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.
    BMC Cancer. 2021;21:678.
    PubMed     Abstract available


  14. CHEN C, Wu Z, Wu Z, Wu C, et al
    Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database.
    BMC Cancer. 2021;21:666.
    PubMed     Abstract available


    May 2021
  15. HUANG A, Xu Y, Zang X, Wu C, et al
    Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    BMC Cancer. 2021;21:634.
    PubMed     Abstract available


  16. SHAN Q, Shi J, Wang X, Guo J, et al
    A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
    BMC Cancer. 2021;21:640.
    PubMed     Abstract available


  17. GUO X, Ma W, Wu H, Xu Y, et al
    Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.
    BMC Cancer. 2021;21:613.
    PubMed     Abstract available


  18. WANG Q, Gao W, Gao F, Jin S, et al
    Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
    BMC Cancer. 2021;21:602.
    PubMed     Abstract available


  19. JARRY U, Bostoen M, Pineau R, Chaillot L, et al
    Correction to: Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
    BMC Cancer. 2021;21:574.
    PubMed    


  20. GO SI, Park MJ, Lee GW
    Clinical significance of the cachexia index in patients with small cell lung cancer.
    BMC Cancer. 2021;21:563.
    PubMed     Abstract available


  21. ZHU D, Ding R, Ma Y, Chen Z, et al
    Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China.
    BMC Cancer. 2021;21:557.
    PubMed     Abstract available


  22. GARGIULO P, Arenare L, Gridelli C, Morabito A, et al
    Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
    BMC Cancer. 2021;21:549.
    PubMed     Abstract available


  23. LEVITSKY A, Bernhardson BM, Henoch I, Olin M, et al
    Using patients' own knowledge of early sensations and symptoms to develop an interactive, individualized e-questionnaire to facilitate early diagnosis of lung cancer.
    BMC Cancer. 2021;21:544.
    PubMed     Abstract available


  24. JARRY U, Bostoen M, Pineau R, Chaillot L, et al
    Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
    BMC Cancer. 2021;21:530.
    PubMed     Abstract available


  25. LESTER J, Escriu C, Khan S, Hudson E, et al
    Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
    BMC Cancer. 2021;21:515.
    PubMed     Abstract available


  26. ZHU L, Zou C, Zhang Z, Wang J, et al
    Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
    BMC Cancer. 2021;21:511.
    PubMed     Abstract available


  27. OKUMURA N, Soh J, Suzuki H, Nakata M, et al
    Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
    BMC Cancer. 2021;21:506.
    PubMed     Abstract available


  28. ZUO T, Lin W, Liu F, Xu J, et al
    Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.
    BMC Cancer. 2021;21:505.
    PubMed     Abstract available


  29. MA J, Li X, Zhao S, Wang J, et al
    Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2021;21:498.
    PubMed     Abstract available


    April 2021
  30. WANG X, Zeng Z, Cai J, Xu P, et al
    Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
    BMC Cancer. 2021;21:482.
    PubMed     Abstract available


  31. YU Y, Ren K
    Five long non-coding RNAs establish a prognostic nomogram and construct a competing endogenous RNA network in the progression of non-small cell lung cancer.
    BMC Cancer. 2021;21:457.
    PubMed     Abstract available


  32. HU J, Chen Y, Zhu X, Ma Q, et al
    Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively.
    BMC Cancer. 2021;21:445.
    PubMed     Abstract available


  33. AYERS KL, Ma M, Debussche G, Corrigan D, et al
    A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    BMC Cancer. 2021;21:441.
    PubMed     Abstract available


  34. HUANG LT, Cao R, Wang YR, Sun L, et al
    Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of ran
    BMC Cancer. 2021;21:426.
    PubMed     Abstract available


  35. ZHANG Y, Simoff MJ, Ost D, Wagner OJ, et al
    Understanding the patient journey to diagnosis of lung cancer.
    BMC Cancer. 2021;21:402.
    PubMed     Abstract available


  36. JOHNSON MK, Wu S, Pankratz DG, Fedorowicz G, et al
    Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules.
    BMC Cancer. 2021;21:400.
    PubMed     Abstract available


  37. STORK T, Boemans R, Hardes J, Streitburger A, et al
    Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma.
    BMC Cancer. 2021;21:375.
    PubMed     Abstract available


  38. HUANG YS, Chen JL, Chen HM, Yeh LH, et al
    Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer.
    BMC Cancer. 2021;21:348.
    PubMed     Abstract available


  39. HOSOYA K, Fujimoto D, Morimoto T, Kumagai T, et al
    Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
    BMC Cancer. 2021;21:346.
    PubMed     Abstract available


  40. BADE BC, Gan G, Li F, Lu L, et al
    "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".
    BMC Cancer. 2021;21:352.
    PubMed     Abstract available


    March 2021
  41. KIM SR, Hong JH, Sung SY, Kim YH, et al
    Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study.
    BMC Cancer. 2021;21:340.
    PubMed     Abstract available


  42. VANTHOMME K, Rosskamp M, De Schutter H, Vandenheede H, et al
    Lung cancer incidence differences in migrant men in Belgium, 2004-2013: histology-specific analyses.
    BMC Cancer. 2021;21:328.
    PubMed     Abstract available


  43. KUO CS, Tung PH, Huang AC, Wang CC, et al
    A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    BMC Cancer. 2021;21:309.
    PubMed     Abstract available


  44. MIYANAGA A, Matsumoto M, Beck JA, Horikawa I, et al
    EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells.
    BMC Cancer. 2021;21:310.
    PubMed     Abstract available


  45. OSELIN K, Pisarev H, Ilau K, Kiivet RA, et al
    Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer.
    BMC Cancer. 2021;21:274.
    PubMed     Abstract available


  46. SUN S, Zane A, Fulton C, Philipoom J, et al
    Statistical and bioinformatic analysis of hemimethylation patterns in non-small cell lung cancer.
    BMC Cancer. 2021;21:268.
    PubMed     Abstract available


  47. LI H, Ding L, Hong X, Chen Y, et al
    Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis.
    BMC Cancer. 2021;21:259.
    PubMed     Abstract available


  48. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    PubMed     Abstract available


  49. XING W, Sun H, Yan C, Zhao C, et al
    A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    BMC Cancer. 2021;21:263.
    PubMed     Abstract available


  50. ZHAO Y, Gao Y, Xu X, Zhou J, et al
    Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    BMC Cancer. 2021;21:257.
    PubMed     Abstract available


  51. TSUCHIYA T, Matsumoto K, Miyazaki T, Doi R, et al
    A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
    BMC Cancer. 2021;21:249.
    PubMed     Abstract available


  52. PROVENCIO M, Terrasa J, Garrido P, Campelo RG, et al
    Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
    BMC Cancer. 2021;21:230.
    PubMed     Abstract available


  53. LI Y, Zhao X, Xiao H, Yang B, et al
    APE1 may influence CD4+ naive T cells on recurrence free survival in early stage NSCLC.
    BMC Cancer. 2021;21:233.
    PubMed     Abstract available


  54. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available


  55. MINEGISHI Y, Yamaguchi O, Sugawara S, Kuyama S, et al
    A phase II study of first-line afatinib for patients aged >/=75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
    BMC Cancer. 2021;21:208.
    PubMed     Abstract available


  56. ZHAI Y, Zhao B, Wang Y, Li L, et al
    Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
    BMC Cancer. 2021;21:213.
    PubMed     Abstract available


    February 2021
  57. ARAUJO LH, Souza BM, Leite LR, Parma SAF, et al
    Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    BMC Cancer. 2021;21:193.
    PubMed     Abstract available


  58. CHEN J, Sun M, Zhou M, Lu R, et al
    Correction to: Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis.
    BMC Cancer. 2021;21:192.
    PubMed    


  59. ZHU D, Cao D, Shen M, Lv J, et al
    Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
    BMC Cancer. 2021;21:176.
    PubMed     Abstract available


  60. ESTER M, Culos-Reed SN, Abdul-Razzak A, Daun JT, et al
    Feasibility of a multimodal exercise, nutrition, and palliative care intervention in advanced lung cancer.
    BMC Cancer. 2021;21:159.
    PubMed     Abstract available


  61. CHEN J, Sun M, Zhou M, Lu R, et al
    Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis.
    BMC Cancer. 2021;21:158.
    PubMed     Abstract available


  62. WANG Y, Liu J, Huang C, Zeng Y, et al
    Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database.
    BMC Cancer. 2021;21:148.
    PubMed     Abstract available


  63. HE Y, Zhao F, Han Q, Zhou Y, et al
    Prognostic nomogram for predicting long-term cancer-specific survival in patients with lung carcinoid tumors.
    BMC Cancer. 2021;21:141.
    PubMed     Abstract available


  64. PAZIK M, Michalska K, Zebrowska-Nawrocka M, Zawadzka I, et al
    Clinical significance of HRAS and KRAS genes expression in patients with non-small-cell lung cancer - preliminary findings.
    BMC Cancer. 2021;21:130.
    PubMed     Abstract available


  65. KIDD J, Cassim S, Rolleston A, Chepulis L, et al
    Ha Ora: secondary care barriers and enablers to early diagnosis of lung cancer for Maori communities.
    BMC Cancer. 2021;21:121.
    PubMed     Abstract available


  66. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available


    January 2021
  67. WAN Y, Yao D, Fang F, Wang Y, et al
    LncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survival.
    BMC Cancer. 2021;21:104.
    PubMed     Abstract available


  68. LI XS, Nie KC, Zheng ZH, Zhou RS, et al
    Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
    BMC Cancer. 2021;21:96.
    PubMed     Abstract available


  69. HAYASHI T, Shimokawa M, Matsuo K, Iihara H, et al
    Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
    BMC Cancer. 2021;21:74.
    PubMed     Abstract available


  70. ZHAO K, Wang C, Shi F, Huang Y, et al
    Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    BMC Cancer. 2021;21:66.
    PubMed     Abstract available


  71. OYA Y, Yoshida T, Asada K, Oguri T, et al
    Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
    BMC Cancer. 2021;21:57.
    PubMed     Abstract available


  72. JI G, Bao T, Li Z, Tang H, et al
    Current lung cancer screening guidelines may miss high-risk population: a real-world study.
    BMC Cancer. 2021;21:50.
    PubMed     Abstract available


  73. PARK S, Lee SY, Kim D, Sim YS, et al
    Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    BMC Cancer. 2021;21:52.
    PubMed     Abstract available


  74. KU GW, Kang Y, Yu SL, Park J, et al
    LncRNA LINC00240 suppresses invasion and migration in non-small cell lung cancer by sponging miR-7-5p.
    BMC Cancer. 2021;21:44.
    PubMed     Abstract available


  75. KIM SR, Chun SH, Kim JR, Kim SY, et al
    The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    BMC Cancer. 2021;21:19.
    PubMed     Abstract available


  76. HESS LM, Han Y, Zhu YE, Bhandari NR, et al
    Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
    BMC Cancer. 2021;21:28.
    PubMed     Abstract available


  77. CORRIVEAU S, Pond GR, Tang GH, Goffin JR, et al
    A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer.
    BMC Cancer. 2021;21:14.
    PubMed     Abstract available


    December 2020
  78. LIN H, Zhang G, Zhang XC, Lian XL, et al
    Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees.
    BMC Cancer. 2020;20:1209.
    PubMed     Abstract available


  79. COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
    Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
    BMC Cancer. 2020;20:1210.
    PubMed     Abstract available


  80. GONG H, Li Y, Yuan Y, Li W, et al
    EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    BMC Cancer. 2020;20:1189.
    PubMed     Abstract available


  81. TSUCHIYA T, Kamohara R, Muraoka M, Nagayasu T, et al
    A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    BMC Cancer. 2020;20:1192.
    PubMed     Abstract available


  82. ZHU X, Han J, Lan H, Lin Q, et al
    A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
    BMC Cancer. 2020;20:1190.
    PubMed     Abstract available


  83. BRUECKL WM, Ficker JH, Zeitler G
    Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
    BMC Cancer. 2020;20:1185.
    PubMed     Abstract available


  84. BOUCHEZ C, Pluvy J, Soussi G, Nguenang M, et al
    Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:1186.
    PubMed     Abstract available


    November 2020
  85. XU L, Xu F, Kong H, Zhao M, et al
    Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study.
    BMC Cancer. 2020;20:1152.
    PubMed     Abstract available


  86. YU X, Wang Y, Yuan Z, Yu H, et al
    Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
    BMC Cancer. 2020;20:1144.
    PubMed     Abstract available


  87. CHAI M, Shi Q
    The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis.
    BMC Cancer. 2020;20:1121.
    PubMed     Abstract available


  88. WANG B, Wang DQ, Lin MS, Lu SP, et al
    Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy.
    BMC Cancer. 2020;20:1112.
    PubMed     Abstract available


  89. HIGASHIYAMA M, Miyazaki R, Yamamoto H, Anayama T, et al
    Preoperative AminoIndex Cancer Screening (AICS) abnormalities predict postoperative recurrence in patients undergoing curative resection for non-small cell lung cancer.
    BMC Cancer. 2020;20:1100.
    PubMed     Abstract available


  90. XU F, Song J, Xu B, Wang J, et al
    Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer.
    BMC Cancer. 2020;20:1089.
    PubMed     Abstract available


  91. WANG H, Yin Y, Wang R, Huang J, et al
    Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia.
    BMC Cancer. 2020;20:1081.
    PubMed     Abstract available


  92. KIM MY, Shin JY, Kim JO, Son KH, et al
    Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
    BMC Cancer. 2020;20:1057.
    PubMed     Abstract available


    October 2020
  93. PARK JY, Lee YJ, Kim T, Lee CY, et al
    Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea.
    BMC Cancer. 2020;20:1040.
    PubMed     Abstract available


  94. HSU YC, Tsai YH, Weng HH, Hsu LS, et al
    Artificial neural networks improve LDCT lung cancer screening: a comparative validation study.
    BMC Cancer. 2020;20:1023.
    PubMed     Abstract available


  95. WANG B, Xu L, Li Q, Man S, et al
    Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
    BMC Cancer. 2020;20:1021.
    PubMed     Abstract available


  96. BATRA A, Sheka D, Kong S, Cheung WY, et al
    Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer.
    BMC Cancer. 2020;20:1004.
    PubMed     Abstract available


  97. YAMAMOTO T, Niibe Y, Aoki M, Shintani T, et al
    Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
    BMC Cancer. 2020;20:997.
    PubMed     Abstract available


  98. LENG D, Yi J, Xiang M, Zhao H, et al
    Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.
    BMC Cancer. 2020;20:986.
    PubMed     Abstract available


  99. KAIRA K, Mouri A, Kato S, Yoshimura K, et al
    A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    BMC Cancer. 2020;20:961.
    PubMed     Abstract available


  100. LEI H, Wang K, Jiang T, Lu J, et al
    KIAA0101 and UbcH10 interact to regulate non-small cell lung cancer cell proliferation by disrupting the function of the spindle assembly checkpoint.
    BMC Cancer. 2020;20:957.
    PubMed     Abstract available


  101. TAKEDA Y, Naka G, Yamaguchi Y, Hashimoto M, et al
    Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
    BMC Cancer. 2020;20:951.
    PubMed     Abstract available


    September 2020
  102. BILGUUN EO, Kaira K, Kawabata-Iwakawa R, Rokudai S, et al
    Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.
    BMC Cancer. 2020;20:935.
    PubMed     Abstract available


  103. REZAEI M, Mostafaei S, Aghaei A, Hosseini N, et al
    The association between HPV gene expression, inflammatory agents and cellular genes involved in EMT in lung cancer tissue.
    BMC Cancer. 2020;20:916.
    PubMed     Abstract available


  104. GRIESHOBER L, Graw S, Barnett MJ, Thornquist MD, et al
    AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality.
    BMC Cancer. 2020;20:905.
    PubMed     Abstract available


  105. XU X, Liu Z, Xiong W, Qiu M, et al
    Combined and interaction effect of chlamydia pneumoniae infection and smoking on lung cancer: a case-control study in Southeast China.
    BMC Cancer. 2020;20:903.
    PubMed     Abstract available


  106. GAO W, Liang J, Ye Y, Lu J, et al
    FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis.
    BMC Cancer. 2020;20:895.
    PubMed     Abstract available


  107. LI L, Yue HC, Han YW, Liu W, et al
    Relationship between the invasion of lymphocytes and cytokines in the tumor microenvironment and the interval after single brachytherapy hypofractionated radiotherapy and conventional fractionation radiotherapy in non-small cell lung Cancer.
    BMC Cancer. 2020;20:893.
    PubMed     Abstract available


  108. JIANG J, Adams HP, Lange M, Siemann S, et al
    Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.
    BMC Cancer. 2020;20:885.
    PubMed     Abstract available


  109. SCHLUCKEBIER L, Caetano R, Garay OU, Montenegro GT, et al
    Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
    BMC Cancer. 2020;20:875.
    PubMed     Abstract available


  110. SHINODA Y, Kobayashi E, Kobayashi H, Mori T, et al
    Prognostic factors of metastatic myxoid liposarcoma.
    BMC Cancer. 2020;20:883.
    PubMed     Abstract available


  111. PARK HY, Hwang J, Kim DH, Jeon SM, et al
    Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea.
    BMC Cancer. 2020;20:846.
    PubMed     Abstract available


  112. BAN WH, Yeo CD, Han S, Kang HS, et al
    Impact of smoking amount on clinicopathological features and survival in non-small cell lung cancer.
    BMC Cancer. 2020;20:848.
    PubMed     Abstract available


  113. WANG J, Liu Z, Pang Q, Zhang T, et al
    Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    BMC Cancer. 2020;20:837.
    PubMed     Abstract available


  114. ARRIETA O, Catalan R, Guzman-Vazquez S, Barron F, et al
    Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
    BMC Cancer. 2020;20:829.
    PubMed     Abstract available


    August 2020
  115. SAURABH K, Shah PP, Doll MA, Siskind LJ, et al
    UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
    BMC Cancer. 2020;20:824.
    PubMed     Abstract available


  116. NAGHIBZADEH-TAHAMI A, Marzban M, Yazdi-Feyzabadi V, Dabiri S, et al
    Is opium use associated with an increased risk of lung cancer? A case-control study.
    BMC Cancer. 2020;20:807.
    PubMed     Abstract available


  117. BU X, Liu J, Wei L, Wang X, et al
    Epidemiological features and survival outcomes in patients with malignant pulmonary blastoma: a US population-based analysis.
    BMC Cancer. 2020;20:811.
    PubMed     Abstract available


  118. DUAN H, Liang L, Xie S, Wang C, et al
    The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
    BMC Cancer. 2020;20:809.
    PubMed     Abstract available


  119. BOZORGMEHR F, Chung I, Christopoulos P, Krisam J, et al
    Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
    BMC Cancer. 2020;20:806.
    PubMed     Abstract available


  120. LI J, Zheng Q, Zhao X, Zhao J, et al
    Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis.
    BMC Cancer. 2020;20:793.
    PubMed     Abstract available


  121. LIANG J, Li J, Li Z, Meng T, et al
    Differentiating the lung lesions using Intravoxel incoherent motion diffusion-weighted imaging: a meta-analysis.
    BMC Cancer. 2020;20:799.
    PubMed     Abstract available


  122. TAKANASHI Y, Funai K, Sato S, Kawase A, et al
    Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.
    BMC Cancer. 2020;20:800.
    PubMed     Abstract available


  123. RADES D, Werner EM, Glatzel E, Eggert MC, et al
    Pneumonitis after radiotherapy for lung cancer (PARALUC): an interventional study to create a symptom-based scoring system for identification of patients developing radiation pneumonitis.
    BMC Cancer. 2020;20:785.
    PubMed     Abstract available


  124. JIANG H, Xu S, Chen C
    A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    BMC Cancer. 2020;20:782.
    PubMed     Abstract available


  125. LORENZO-LUACES P, Sanchez L, Saavedra D, Crombet T, et al
    Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
    BMC Cancer. 2020;20:772.
    PubMed     Abstract available


  126. ZHONG L, Xie L, Yang Z, Li L, et al
    Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
    BMC Cancer. 2020;20:766.
    PubMed     Abstract available


  127. DICKHOFF C, Senan S, Schneiders FL, Veltman J, et al
    Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
    BMC Cancer. 2020;20:764.
    PubMed     Abstract available


  128. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    PubMed     Abstract available


  129. RAMELOW J, Brooks CD, Gao L, Almiman AA, et al
    The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
    BMC Cancer. 2020;20:738.
    PubMed     Abstract available


  130. WU X, Zhang X, Tao L, Chen P, et al
    Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC).
    BMC Cancer. 2020;20:719.
    PubMed     Abstract available


    July 2020
  131. JIA M, Yu S, Yu J, Li Y, et al
    Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system.
    BMC Cancer. 2020;20:705.
    PubMed     Abstract available


  132. CHEN Y, Hu J, Bu F, Zhang H, et al
    Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:707.
    PubMed     Abstract available


  133. OUYANG W, Yu J, Zhou Y, Hu J, et al
    Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
    BMC Cancer. 2020;20:699.
    PubMed     Abstract available


  134. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
    Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC Cancer. 2020;20:690.
    PubMed     Abstract available


  135. JIA B, Zheng Q, Wang J, Sun H, et al
    A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database.
    BMC Cancer. 2020;20:666.
    PubMed     Abstract available


  136. AYE PS, Tin Tin S, McKeage MJ, Khwaounjoo P, et al
    Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    BMC Cancer. 2020;20:658.
    PubMed     Abstract available


  137. SUN Y, Wu M, Zhou M, Luo X, et al
    Management of medically inoperable and tyrosine kinase inhibitor-naive early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    BMC Cancer. 2020;20:646.
    PubMed     Abstract available


  138. PAN ST, Zhou J, Yang F, Zhou SF, et al
    Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells.
    BMC Cancer. 2020;20:634.
    PubMed     Abstract available


  139. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available


    June 2020
  140. XU T, Zhang X, Zhang S, Liu C, et al
    Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
    BMC Cancer. 2020;20:596.
    PubMed     Abstract available


  141. MA F, Xie Y, Lei Y, Kuang Z, et al
    The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer.
    BMC Cancer. 2020;20:580.
    PubMed     Abstract available


  142. KANG DH, Jung SS, Yeo MK, Lee DH, et al
    Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    BMC Cancer. 2020;20:571.
    PubMed     Abstract available


  143. TENG X, Wei L, Han L, Min D, et al
    Establishment of a serological molecular model for the early diagnosis and progression monitoring of bone metastasis in lung cancer.
    BMC Cancer. 2020;20:562.
    PubMed     Abstract available


  144. LAKE M, Shusted CS, Juon HS, McIntire RK, et al
    Black patients referred to a lung cancer screening program experience lower rates of screening and longer time to follow-up.
    BMC Cancer. 2020;20:561.
    PubMed     Abstract available


  145. LIEVERSE RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, et al
    Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
    BMC Cancer. 2020;20:557.
    PubMed     Abstract available


  146. HUANG T, Sun H, Luo X, Zhang X, et al
    Correlation study between flash dual source CT perfusion imaging and regional lymph node metastasis of non-small cell lung cancer.
    BMC Cancer. 2020;20:547.
    PubMed     Abstract available


  147. LIU Q, Huang Y, Chen H, Liu Y, et al
    The development and validation of a radiomic nomogram for the preoperative prediction of lung adenocarcinoma.
    BMC Cancer. 2020;20:533.
    PubMed     Abstract available


  148. LIU Y, Zhu Y, Bai L, Chen F, et al
    Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma.
    BMC Cancer. 2020;20:520.
    PubMed     Abstract available


  149. KOSHIMUNE S, Kosaka M, Mizuno N, Yamamoto H, et al
    Prognostic value of OCT4A and SPP1C transcript variant co-expression in early-stage lung adenocarcinoma.
    BMC Cancer. 2020;20:521.
    PubMed     Abstract available


  150. CHEN J, Xia J, Huang J, Xu R, et al
    Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis.
    BMC Cancer. 2020;20:510.
    PubMed     Abstract available


  151. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available


    May 2020
  152. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available


  153. EL YACOUBI H, Sow ML, Kettani F, Gamra L, et al
    Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
    BMC Cancer. 2020;20:479.
    PubMed     Abstract available


  154. SOLARI JIG, Filippi-Chiela E, Pilar ES, Nunes V, et al
    Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
    BMC Cancer. 2020;20:474.
    PubMed     Abstract available


  155. HOWLETT J, Benzenine E, Cottenet J, Foucher P, et al
    Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study.
    BMC Cancer. 2020;20:461.
    PubMed     Abstract available


  156. KESSEL KA, Grosser RCE, Kraus KM, Hoffmann H, et al
    Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO).
    BMC Cancer. 2020;20:442.
    PubMed     Abstract available


  157. DE MOL M, Visser S, Aerts J, Lodder P, et al
    The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.
    BMC Cancer. 2020;20:431.
    PubMed     Abstract available


  158. WU X, Yu W, Petersen RH, Sheng H, et al
    A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma.
    BMC Cancer. 2020;20:429.
    PubMed     Abstract available


  159. HU L, Zhang P, Mei Q, Sun W, et al
    Podoplanin is a useful prognostic marker and indicates better differentiation in lung squamous cell cancer patients? A systematic review and meta-analysis.
    BMC Cancer. 2020;20:424.
    PubMed     Abstract available


  160. WAGENER-RYCZEK S, Heydt C, Suptitz J, Michels S, et al
    Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:408.
    PubMed     Abstract available


  161. KALINAUSKAITE GG, Tinhofer II, Kufeld MM, Kluge AA, et al
    Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
    BMC Cancer. 2020;20:404.
    PubMed     Abstract available


  162. BERKOVIC P, Gulyban A, Defraene G, Swenen L, et al
    Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases.
    BMC Cancer. 2020;20:402.
    PubMed     Abstract available


  163. YOON SH, Kim HS, Kim RN, Jung SY, et al
    NAD(P)-dependent steroid dehydrogenase-like is involved in breast cancer cell growth and metastasis.
    BMC Cancer. 2020;20:375.
    PubMed     Abstract available


  164. KEPPENS C, Dequeker EMC, Rouleau E, 't Hart N, et al
    Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples.
    BMC Cancer. 2020;20:366.
    PubMed     Abstract available


  165. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
    A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    BMC Cancer. 2020;20:370.
    PubMed     Abstract available


    April 2020
  166. CHIANG AC, Fernandes AW, Pavilack M, Wu JW, et al
    EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:356.
    PubMed     Abstract available


  167. KITAGAWA Y, Osumi H, Shinozaki E, Ota Y, et al
    Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective stud
    BMC Cancer. 2020;20:358.
    PubMed     Abstract available


  168. ZOU Y, Xu L, Tang Q, You Q, et al
    Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    BMC Cancer. 2020;20:344.
    PubMed     Abstract available


  169. HAZELL SZ, Mai N, Fu W, Hu C, et al
    Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impact.
    BMC Cancer. 2020;20:334.
    PubMed     Abstract available


  170. QIN K, Hou H, Liang Y, Zhang X, et al
    Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2020;20:328.
    PubMed     Abstract available


  171. JIN X, Guan Y, Zhang Z, Wang H, et al
    Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer.
    BMC Cancer. 2020;20:329.
    PubMed     Abstract available


  172. YAO W, Wang L, Huang H, Li X, et al
    All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
    BMC Cancer. 2020;20:315.
    PubMed     Abstract available


  173. SHEILL G, Guinan E, O'Neill L, Normand C, et al
    Preoperative exercise to improve fitness in patients undergoing complex surgery for cancer of the lung or oesophagus (PRE-HIIT): protocol for a randomized controlled trial.
    BMC Cancer. 2020;20:321.
    PubMed     Abstract available


  174. SHAH N, Liu Z, Tallman RM, Mohammad A, et al
    Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
    BMC Cancer. 2020;20:292.
    PubMed     Abstract available


  175. STEEGHS EMP, Kroeze LI, Tops BBJ, van Kempen LC, et al
    Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    BMC Cancer. 2020;20:291.
    PubMed     Abstract available


  176. SANO K, Nakadate K, Hanada K
    Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.
    BMC Cancer. 2020;20:279.
    PubMed     Abstract available


  177. BI N, Liu L, Liang J, Wu S, et al
    Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
    BMC Cancer. 2020;20:278.
    PubMed     Abstract available


  178. HANSEN RN, Zhang Y, Seal B, Ryan K, et al
    Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
    BMC Cancer. 2020;20:276.
    PubMed     Abstract available


  179. DELGADO-GARCIA M, Weynand B, Gomez-Izquierdo L, Hernandez MJ, et al
    Clinical performance evaluation of the Idylla EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.
    BMC Cancer. 2020;20:275.
    PubMed     Abstract available


    March 2020
  180. HARDTSTOCK F, Myers D, Li T, Cizova D, et al
    Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
    BMC Cancer. 2020;20:260.
    PubMed     Abstract available


  181. XU N, Liu F, Wu S, Ye M, et al
    CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.
    BMC Cancer. 2020;20:262.
    PubMed     Abstract available


  182. DING R, Zhu D, He P, Ma Y, et al
    Comorbidity in lung cancer patients and its association with medical service cost and treatment choice in China.
    BMC Cancer. 2020;20:250.
    PubMed     Abstract available


  183. ZHAO J, Xiang C, Zhao R, Guo P, et al
    Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma.
    BMC Cancer. 2020;20:248.
    PubMed     Abstract available


  184. SIEBENHUNER AR, Guller U, Warschkow R
    Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.
    BMC Cancer. 2020;20:246.
    PubMed     Abstract available


  185. NAWROCKI S, Sugajska A
    Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
    BMC Cancer. 2020;20:231.
    PubMed     Abstract available


  186. MOSS C, Haire A, Cahill F, Enting D, et al
    Guy's cancer cohort - real world evidence for cancer pathways.
    BMC Cancer. 2020;20:187.
    PubMed     Abstract available


  187. TOZUKA T, Kitazono S, Sakamoto H, Yoshida H, et al
    Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
    BMC Cancer. 2020;20:207.
    PubMed     Abstract available


  188. YANG F, Hu M, Chang S, Huang J, et al
    Alteration in the sensitivity to crizotinib by Na(+)/H(+) exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers.
    BMC Cancer. 2020;20:202.
    PubMed     Abstract available


  189. DIMOU A, Barron G, Merrick DT, Kolfenbach J, et al
    Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
    BMC Cancer. 2020;20:177.
    PubMed     Abstract available


    February 2020
  190. LUO P, Yang X, Huang S, Feng S, et al
    Syntenin overexpression in human lung cancer tissue and serum is associated with poor prognosis.
    BMC Cancer. 2020;20:159.
    PubMed     Abstract available


  191. DREVINSKAITE M, Patasius A, Kevlicius L, Mickys U, et al
    Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature.
    BMC Cancer. 2020;20:162.
    PubMed     Abstract available


  192. ADACHI Y, Yanagimura N, Suzuki C, Ootani S, et al
    Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
    BMC Cancer. 2020;20:156.
    PubMed     Abstract available


  193. WANG C, Wu Y, Shao J, Liu D, et al
    Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer.
    BMC Cancer. 2020;20:150.
    PubMed     Abstract available


  194. CAI Y, Wu H, Shi X, Dong Y, et al
    Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
    BMC Cancer. 2020;20:148.
    PubMed     Abstract available


  195. DUTTA P, Zhang L, Zhang H, Peng Q, et al
    Unphosphorylated STAT3 in heterochromatin formation and tumor suppression in lung cancer.
    BMC Cancer. 2020;20:145.
    PubMed     Abstract available


  196. GOEBEL C, Louden CL, Mckenna R Jr, Onugha O, et al
    Blood test shows high accuracy in detecting stage I non-small cell lung cancer.
    BMC Cancer. 2020;20:137.
    PubMed     Abstract available


  197. HATTORI Y, Kono Y, Itoh S, Inoue T, et al
    A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2020;20:115.
    PubMed     Abstract available


  198. LAWRENSON R, Lao C, Brown L, Moosa L, et al
    Management of patients with early stage lung cancer - why do some patients not receive treatment with curative intent?
    BMC Cancer. 2020;20:109.
    PubMed     Abstract available


  199. ZHENG J, Ye X, Liu Y, Zhao Y, et al
    The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer.
    BMC Cancer. 2020;20:106.
    PubMed     Abstract available


  200. TOKUDOME N, Koh Y, Akamatsu H, Fujimoto D, et al
    Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
    BMC Cancer. 2020;20:103.
    PubMed     Abstract available


  201. KOGO M, Fujimoto D, Hosoya K, Nagata K, et al
    Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
    BMC Cancer. 2020;20:104.
    PubMed     Abstract available


  202. MORITA M, Tamiya M, Fujimoto D, Tamiya A, et al
    Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
    BMC Cancer. 2020;20:93.
    PubMed     Abstract available


    January 2020
  203. RUIZ-CORDERO R, Ma J, Khanna A, Lyons G, et al
    Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
    BMC Cancer. 2020;20:83.
    PubMed     Abstract available


  204. LIU K, Jiang G, Zhang A, Li Z, et al
    Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    BMC Cancer. 2020;20:76.
    PubMed     Abstract available


  205. LI X, Zhang W, Yu Y, Zhang G, et al
    CT features and quantitative analysis of subsolid nodule lung adenocarcinoma for pathological classification prediction.
    BMC Cancer. 2020;20:60.
    PubMed     Abstract available


  206. FOWLER H, Belot A, Ellis L, Maringe C, et al
    Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers.
    BMC Cancer. 2020;20:2.
    PubMed     Abstract available


  207. LV Z, Lei T
    Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
    BMC Cancer. 2020;20:56.
    PubMed     Abstract available


  208. TIAN H, Shi G, Yang G, Zhang J, et al
    Correction to: Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
    BMC Cancer. 2020;20:42.
    PubMed     Abstract available


  209. HARLE A, Molassiotis A, Buffin O, Burnham J, et al
    A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need.
    BMC Cancer. 2020;20:9.
    PubMed     Abstract available


  210. GUISIER F, Piton N, Bellefleur M, Delberghe N, et al
    Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
    BMC Cancer. 2020;20:14.
    PubMed     Abstract available


    December 2019
  211. SUN H, Zhang G, Ai B, Zhang H, et al
    A systematic review: comparative analysis of the effects of propofol and sevoflurane on postoperative cognitive function in elderly patients with lung cancer.
    BMC Cancer. 2019;19:1248.
    PubMed     Abstract available


  212. KISSEL M, Martel-Lafay I, Lequesne J, Faivre JC, et al
    Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    BMC Cancer. 2019;19:1237.
    PubMed     Abstract available


  213. PALMA DA, Chen H, Bahig H, Gaede S, et al
    Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.
    BMC Cancer. 2019;19:1206.
    PubMed     Abstract available


  214. GE P, Cao L, Chen X, Jing R, et al
    miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    BMC Cancer. 2019;19:1203.
    PubMed     Abstract available


  215. GUAN J, Luo Z, Xiao Z, Xie Y, et al
    Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
    BMC Cancer. 2019;19:1188.
    PubMed     Abstract available


  216. SMOLANDER J, Stupnikov A, Glazko G, Dehmer M, et al
    Comparing biological information contained in mRNA and non-coding RNAs for classification of lung cancer patients.
    BMC Cancer. 2019;19:1176.
    PubMed     Abstract available


  217. WU L, Wang W, Dai M, Li H, et al
    PPARalpha ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.
    BMC Cancer. 2019;19:1166.
    PubMed     Abstract available


    November 2019
  218. TENG X, Teng X
    First report of pulmonary sclerosing pneomucytoma with malignant transformation in both cuboidal surface cells and stromal round cells: a case report.
    BMC Cancer. 2019;19:1154.
    PubMed     Abstract available


  219. KATSUI K, Ogata T, Watanabe K, Katayama N, et al
    Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
    BMC Cancer. 2019;19:1144.
    PubMed     Abstract available


  220. HANSEN MS, Licaj I, Braaten T, Langhammer A, et al
    Smoking related lung cancer mortality by education and sex in Norway.
    BMC Cancer. 2019;19:1132.
    PubMed    


  221. SHAO C, Yang F, Qin Z, Jing X, et al
    The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis.
    BMC Cancer. 2019;19:1103.
    PubMed     Abstract available


  222. LI Z, Shen D, Zhang J, Zhang J, et al
    Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
    BMC Cancer. 2019;19:1104.
    PubMed     Abstract available


  223. CRAIG DJ, Morrison T, Khuder SA, Crawford EL, et al
    Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
    BMC Cancer. 2019;19:1081.
    PubMed     Abstract available


  224. BOZORGMEHR F, Hommertgen A, Krisam J, Lasitschka F, et al
    Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    BMC Cancer. 2019;19:1074.
    PubMed     Abstract available


  225. CHENG YI, Gan YC, Liu D, Davies MPA, et al
    Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review.
    BMC Cancer. 2019;19:1068.
    PubMed     Abstract available


  226. ZHANG JT, Liu SY, Yan HH, Wu YL, et al
    Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2019;19:1051.
    PubMed     Abstract available


    October 2019
  227. SU L, Chen M, Su H, Dai Y, et al
    Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis.
    BMC Cancer. 2019;19:1023.
    PubMed     Abstract available


  228. CHEN YH, Chen YF, Chen CY, Shih JY, et al
    Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    BMC Cancer. 2019;19:1006.
    PubMed     Abstract available


  229. YAMAGUCHI A, Achmad A, Hanaoka H, Heryanto YD, et al
    Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
    BMC Cancer. 2019;19:1000.
    PubMed     Abstract available


  230. DARBA J, Marsa A
    The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period.
    BMC Cancer. 2019;19:992.
    PubMed     Abstract available


  231. STOPPEK AK, Kebir S, Junker A, Keyvani K, et al
    Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.
    BMC Cancer. 2019;19:995.
    PubMed     Abstract available


  232. CHANG YF, Lim KH, Chiang YW, Sie ZL, et al
    STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers.
    BMC Cancer. 2019;19:959.
    PubMed     Abstract available


  233. YANG Z, Liu C, Wu H, Xie Y, et al
    CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29.
    BMC Cancer. 2019;19:948.
    PubMed     Abstract available


    September 2019
  234. DE HAAN R, van Werkhoven E, van den Heuvel MM, Peulen HMU, et al
    Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
    BMC Cancer. 2019;19:901.
    PubMed     Abstract available


  235. PIAO L, Yang Z, Feng Y, Zhang C, et al
    LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma.
    BMC Cancer. 2019;19:898.
    PubMed     Abstract available


  236. HO GF, Chai CS, Alip A, Wahid MIA, et al
    Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
    BMC Cancer. 2019;19:896.
    PubMed     Abstract available


  237. LI L, Yan S, Zhang H, Zhang M, et al
    Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-beta1-mediated epithelial to mesenchymal transition in lung cancer cells.
    BMC Cancer. 2019;19:894.
    PubMed     Abstract available


  238. LI Y, Ge D, Gu J, Xu F, et al
    A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    BMC Cancer. 2019;19:886.
    PubMed     Abstract available


    August 2019
  239. BAYAT MOKHTARI R, Baluch N, Morgatskaya E, Kumar S, et al
    Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane.
    BMC Cancer. 2019;19:864.
    PubMed     Abstract available


  240. MOVIA D, Bazou D, Prina-Mello A
    ALI multilayered co-cultures mimic biochemical mechanisms of the cancer cell-fibroblast cross-talk involved in NSCLC MultiDrug Resistance.
    BMC Cancer. 2019;19:854.
    PubMed     Abstract available


  241. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available


  242. ISLAM KM, Anggondowati T, Deviany PE, Ryan JE, et al
    Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer.
    BMC Cancer. 2019;19:835.
    PubMed     Abstract available


  243. CHOWDHURY P, Dey P, Ghosh S, Sarma A, et al
    Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
    BMC Cancer. 2019;19:829.
    PubMed     Abstract available


  244. LUCCHETTA M, da Piedade I, Mounir M, Vabistsevits M, et al
    Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response.
    BMC Cancer. 2019;19:824.
    PubMed     Abstract available


  245. KIM KH, Chung C, Kim JM, Lee D, et al
    Clinical significance of atypical protein kinase C (PKCiota and PKCzeta) and its relationship with yes-associated protein in lung adenocarcinoma.
    BMC Cancer. 2019;19:804.
    PubMed     Abstract available


  246. FENG YH, Su YC, Lin SF, Lin PR, et al
    Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer.
    BMC Cancer. 2019;19:791.
    PubMed     Abstract available


  247. CHEN Y, Wei J, Cai J, Liu A, et al
    Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    BMC Cancer. 2019;19:793.
    PubMed     Abstract available


  248. CHEN Z, Teng X, Zhang J, Huang K, et al
    Molecular features of lung adenocarcinoma in young patients.
    BMC Cancer. 2019;19:777.
    PubMed     Abstract available


  249. XU S, Wang W, Xu C, Li X, et al
    ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    BMC Cancer. 2019;19:769.
    PubMed     Abstract available


    July 2019
  250. DJUREINOVIC D, Ponten V, Landelius P, Al Sayegh S, et al
    Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.
    BMC Cancer. 2019;19:741.
    PubMed     Abstract available


  251. YU H, Sun J, Zhao C, Wang H, et al
    SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients.
    BMC Cancer. 2019;19:736.
    PubMed     Abstract available


  252. CHANTHARASAMEE J, Poungvarin N, Danchaivijitr P, Techawatanawanna S, et al
    Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    BMC Cancer. 2019;19:701.
    PubMed     Abstract available


  253. LIU J, Jin B, Su H, Qu X, et al
    Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    BMC Cancer. 2019;19:702.
    PubMed     Abstract available


  254. GUAN X, Ma CX, Quan JC, Li S, et al
    A clinical model to predict the risk of synchronous bone metastasis in newly diagnosed colorectal cancer: a population-based study.
    BMC Cancer. 2019;19:704.
    PubMed     Abstract available


  255. LI J, Shen C, Wang X, Lai Y, et al
    Prognostic value of TGF-beta in lung cancer: systematic review and meta-analysis.
    BMC Cancer. 2019;19:691.
    PubMed     Abstract available


  256. SONG J, Wang W, Wang Y, Qin Y, et al
    Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma.
    BMC Cancer. 2019;19:680.
    PubMed     Abstract available


  257. ZHANG Y, Sun L, Gao X, Guo A, et al
    RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.
    BMC Cancer. 2019;19:670.
    PubMed     Abstract available


    June 2019
  258. DUBAERE E, Goffaux M, Wanet M, Bihin B, et al
    Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
    BMC Cancer. 2019;19:639.
    PubMed     Abstract available


  259. ZHOU Y, Sinha S, Schwartz JL, Adami GR, et al
    A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA.
    BMC Cancer. 2019;19:607.
    PubMed     Abstract available


  260. BECK TN, Boumber YA, Aggarwal C, Pei J, et al
    Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.
    BMC Cancer. 2019;19:603.
    PubMed     Abstract available


  261. LAI J, Yang H, Zhu Y, Ruan M, et al
    MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    BMC Cancer. 2019;19:602.
    PubMed     Abstract available


  262. FANG W, Huang Y, Hong S, Zhang Z, et al
    EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
    BMC Cancer. 2019;19:595.
    PubMed     Abstract available


  263. SHANG X, Liu J, Li Z, Lin J, et al
    A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC.
    BMC Cancer. 2019;19:591.
    PubMed     Abstract available


  264. ANDRIES V, De Keuckelaere E, Staes K, Hochepied T, et al
    A new mouse model to study the role of ectopic Nanos3 expression in cancer.
    BMC Cancer. 2019;19:598.
    PubMed     Abstract available


  265. XU M, Wang X, Pan Y, Zhao X, et al
    Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    BMC Cancer. 2019;19:599.
    PubMed     Abstract available


  266. GE J, Yao B, Huang J, Wu X, et al
    Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report.
    BMC Cancer. 2019;19:592.
    PubMed     Abstract available


  267. CHEN G, Dong B, Shan G, Zhang X, et al
    Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI.
    BMC Cancer. 2019;19:583.
    PubMed     Abstract available


  268. KANG G, Chen K, Yang F, Chuai S, et al
    Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study.
    BMC Cancer. 2019;19:579.
    PubMed     Abstract available


  269. PARK JY, Jang SH, Kim HI, Kim JH, et al
    Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    BMC Cancer. 2019;19:574.
    PubMed     Abstract available


  270. CALLEBOUT E, Ribeiro SM, Laurent S, De Man M, et al
    Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    BMC Cancer. 2019;19:567.
    PubMed     Abstract available


  271. KAREDATH T, Ahmed I, Al Ameri W, Al-Dasim FM, et al
    Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes.
    BMC Cancer. 2019;19:565.
    PubMed     Abstract available


  272. KOSAKA T, Hongo H, Oya M
    Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    BMC Cancer. 2019;19:562.
    PubMed     Abstract available


  273. SUN X, Roudi R, Dai T, Chen S, et al
    Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    BMC Cancer. 2019;19:558.
    PubMed     Abstract available


  274. TSUNODA A, Morikawa K, Inoue T, Miyazawa T, et al
    A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    BMC Cancer. 2019;19:546.
    PubMed     Abstract available


    May 2019
  275. MIURA S, Naito T, Mitsunaga S, Omae K, et al
    A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.
    BMC Cancer. 2019;19:528.
    PubMed     Abstract available


  276. KETTUNEN E, Savukoski S, Salmenkivi K, Bohling T, et al
    CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    BMC Cancer. 2019;19:507.
    PubMed     Abstract available


  277. BHAT GR, Bhat A, Verma S, Sethi I, et al
    Association of newly identified genetic variant rs2853677 of TERT with non-small cell lung cancer and leukemia in population of Jammu and Kashmir, India.
    BMC Cancer. 2019;19:493.
    PubMed     Abstract available


  278. WANG W, Men Y, Wang J, Zhou Z, et al
    Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
    BMC Cancer. 2019;19:478.
    PubMed     Abstract available


  279. VAN NEST SJ, Nicholson LM, Pavey N, Hindi MN, et al
    Raman spectroscopy detects metabolic signatures of radiation response and hypoxic fluctuations in non-small cell lung cancer.
    BMC Cancer. 2019;19:474.
    PubMed     Abstract available


  280. YU L, Tao G, Zhu L, Wang G, et al
    Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis.
    BMC Cancer. 2019;19:464.
    PubMed     Abstract available


  281. BAI H, Wang C, Qi Y, Xu J, et al
    Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway.
    BMC Cancer. 2019;19:454.
    PubMed     Abstract available


  282. VISSER S, Hou J, Bezemer K, de Vogel LL, et al
    Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles.
    BMC Cancer. 2019;19:440.
    PubMed     Abstract available


  283. ZHAO F, Zhen FX, Zhou Y, Huang CJ, et al
    Clinicopathologic predictors of metastasis of different regional lymph nodes in patients intraoperatively diagnosed with stage-I non-small cell lung cancer.
    BMC Cancer. 2019;19:444.
    PubMed     Abstract available


  284. KHADDOUR K, Singh V, Shayuk M
    Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review.
    BMC Cancer. 2019;19:449.
    PubMed     Abstract available


  285. ZAHN MO, Linck D, Losem C, Gessner C, et al
    AVAiLABLE NIS - AVASTIN(R) in lung cancer treatment in routine oncology practice in Germany.
    BMC Cancer. 2019;19:433.
    PubMed     Abstract available


  286. SUWINSKI R, Giglok M, Galwas-Kliber K, Idasiak A, et al
    Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
    BMC Cancer. 2019;19:427.
    PubMed     Abstract available


  287. EICHHORN F, Klotz LV, Bischoff H, Thomas M, et al
    Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    BMC Cancer. 2019;19:413.
    PubMed     Abstract available


    April 2019
  288. DEL RE M, Rofi E, Cappelli C, Puppo G, et al
    The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.
    BMC Cancer. 2019;19:410.
    PubMed     Abstract available


  289. D'ALMEIDA PRETO D, Baston MT, Geraige CC, Augusto SB, et al
    Impact of AferBio(R) on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial.
    BMC Cancer. 2019;19:382.
    PubMed     Abstract available


  290. CONNOCK M, Armoiry X, Tsertsvadze A, Melendez-Torres GJ, et al
    Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and sec
    BMC Cancer. 2019;19:392.
    PubMed     Abstract available


  291. NAGAMATSU Y, Oze I, Aoe K, Hotta K, et al
    Physician requests by patients with malignant pleural mesothelioma in Japan.
    BMC Cancer. 2019;19:383.
    PubMed     Abstract available


  292. BECK TN, Kudinov AE, Dulaimi E, Boumber Y, et al
    Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    BMC Cancer. 2019;19:379.
    PubMed     Abstract available


  293. GUO L, Chen Z, Xu C, Zhang X, et al
    Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level.
    BMC Cancer. 2019;19:369.
    PubMed     Abstract available


  294. VICKERS AD, Winfree KB, Cuyun Carter G, Kiiskinen U, et al
    Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2019;19:353.
    PubMed     Abstract available


  295. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Horlings HM, et al
    A specific gene expression signature for visceral organ metastasis in breast cancer.
    BMC Cancer. 2019;19:333.
    PubMed     Abstract available


  296. KURODA A, Tabuchi T, Iwami E, Sasahara K, et al
    Abscopal effect of radiation on multiple lung metastases of lung adenocarcinoma: a case report.
    BMC Cancer. 2019;19:336.
    PubMed     Abstract available


  297. SUMODHEE S, Bondiau PY, Poudenx M, Cohen C, et al
    Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
    BMC Cancer. 2019;19:305.
    PubMed     Abstract available


  298. FURUGAKI K, Mochizuki M, Kohno M, Shu S, et al
    Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    BMC Cancer. 2019;19:301.
    PubMed     Abstract available


  299. CHO YJ, Cho YM, Kim SH, Shin KH, et al
    Clinical analysis of patients with skeletal metastasis of lung cancer.
    BMC Cancer. 2019;19:303.
    PubMed     Abstract available


  300. WANG L, Meng Y, Zhang QY
    LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR.
    BMC Cancer. 2019;19:293.
    PubMed     Abstract available


    March 2019
  301. CHEN Y, Tsang YS, Chou X, Hu J, et al
    A lung cancer patient with deep vein thrombosis:a case report and literature review.
    BMC Cancer. 2019;19:285.
    PubMed     Abstract available


  302. YING J, Zhou D, Gu T, Huang J, et al
    Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
    BMC Cancer. 2019;19:288.
    PubMed     Abstract available


  303. GUO CY, Zhu Q, Tou FF, Wen XM, et al
    The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
    BMC Cancer. 2019;19:289.
    PubMed     Abstract available


  304. ZHAO P, Wu J, Lu F, Peng X, et al
    Correction to: The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
    BMC Cancer. 2019;19:269.
    PubMed     Abstract available


  305. YANG LH, Han Y, Li G, Xu HT, et al
    Correction to: Axin gene methylation status correlates with radiosensitivity of lung cancer cells.
    BMC Cancer. 2019;19:268.
    PubMed     Abstract available


  306. YU J, Hu Y, Xu Y, Wang J, et al
    LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features.
    BMC Cancer. 2019;19:263.
    PubMed     Abstract available


  307. SONE K, Oguri T, Uemura T, Takeuchi A, et al
    Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
    BMC Cancer. 2019;19:246.
    PubMed     Abstract available


  308. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
    The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study.
    BMC Cancer. 2019;19:241.
    PubMed     Abstract available


  309. ZHANG C, Mao M, Guo X, Cui P, et al
    Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer.
    BMC Cancer. 2019;19:238.
    PubMed     Abstract available


  310. ZHAO J, Teng H, Zhao R, Ding W, et al
    Malignant perivascular epithelioid cell tumor of the lung synchronous with a primary adenocarcinoma: one case report and review of the literature.
    BMC Cancer. 2019;19:235.
    PubMed     Abstract available


  311. ESFANDI F, Taheri M, Omrani MD, Shadmehr MB, et al
    Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues.
    BMC Cancer. 2019;19:222.
    PubMed     Abstract available


  312. WOOD R, Taylor-Stokes G
    Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
    BMC Cancer. 2019;19:214.
    PubMed     Abstract available


  313. LU L, Liu Q, Wang P, Wu Y, et al
    MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway.
    BMC Cancer. 2019;19:209.
    PubMed     Abstract available


  314. ZHAO P, Wu J, Lu F, Peng X, et al
    The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
    BMC Cancer. 2019;19:201.
    PubMed     Abstract available


    February 2019
  315. NUKII Y, Miyamoto A, Mochizuki S, Moriguchi S, et al
    Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report.
    BMC Cancer. 2019;19:186.
    PubMed     Abstract available


  316. NAMBA K, Tomida S, Matsubara T, Takahashi Y, et al
    Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naive lung adenocarcinoma.
    BMC Cancer. 2019;19:175.
    PubMed     Abstract available


  317. KLEMENT RJ, Abbasi-Senger N, Adebahr S, Alheid H, et al
    The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
    BMC Cancer. 2019;19:173.
    PubMed     Abstract available


  318. BERGAMINO M, Rullan AJ, Saigi M, Peiro I, et al
    Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    BMC Cancer. 2019;19:165.
    PubMed     Abstract available


  319. SHIRASAWA M, Fukui T, Kusuhara S, Hiyoshi Y, et al
    Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
    BMC Cancer. 2019;19:163.
    PubMed     Abstract available


  320. LI WY, Zhao TT, Xu HM, Wang ZN, et al
    The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:145.
    PubMed     Abstract available


  321. KANG N, Choi SY, Kim BN, Yeo CD, et al
    Hypoxia-induced cancer stemness acquisition is associated with CXCR4 activation by its aberrant promoter demethylation.
    BMC Cancer. 2019;19:148.
    PubMed     Abstract available


  322. GE M, Zhan Q, Zhang Z, Ji X, et al
    Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
    BMC Cancer. 2019;19:143.
    PubMed     Abstract available


  323. D'ALMEIDA O, Mothar O, Bondzie EA, Lieumo Y, et al
    Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.
    BMC Cancer. 2019;19:136.
    PubMed     Abstract available


  324. WANG J, Chen J
    Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
    BMC Cancer. 2019;19:131.
    PubMed     Abstract available


    January 2019
  325. BORCHERT S, Wessolly M, Schmeller J, Mairinger E, et al
    Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    BMC Cancer. 2019;19:108.
    PubMed     Abstract available


  326. IMAKITA T, Matsumoto H, Hirano K, Morisawa T, et al
    Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
    BMC Cancer. 2019;19:105.
    PubMed     Abstract available


  327. YIN X, Yan D, Qiu M, Huang L, et al
    Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:95.
    PubMed     Abstract available


  328. CEA SORIANO L, Zong J, Garcia Rodriguez LA
    Feasibility and validity of The Health Improvement Network database of primary care electronic health records to identify and characterise patients with small cell lung cancer in the United Kingdom.
    BMC Cancer. 2019;19:91.
    PubMed     Abstract available


  329. ROMINE PE, Martins RG, Eaton KD, Wood DE, et al
    Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
    BMC Cancer. 2019;19:70.
    PubMed     Abstract available


  330. HABEL N, Stefanovska B, Carene D, Patino-Garcia A, et al
    CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rbeta-dependent EMT-like process.
    BMC Cancer. 2019;19:62.
    PubMed     Abstract available


  331. LI M, Li H, Hong G, Tang Z, et al
    Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
    BMC Cancer. 2019;19:67.
    PubMed     Abstract available


  332. ABE M, Watanabe K, Shinozaki-Ushiku A, Ushiku T, et al
    Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review.
    BMC Cancer. 2019;19:52.
    PubMed     Abstract available


  333. CASSIM S, Chepulis L, Keenan R, Kidd J, et al
    Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review.
    BMC Cancer. 2019;19:25.
    PubMed     Abstract available


  334. YAN S, Sun R, Wu S, Jin T, et al
    Single nucleotide polymorphism in the 3' untranslated region of LPP is a risk factor for lung cancer: a case-control study.
    BMC Cancer. 2019;19:35.
    PubMed     Abstract available


  335. SIRIWARDHANA C, Khadka VS, Chen JJ, Deng Y, et al
    Development of a miRNA-seq based prognostic signature in lung adenocarcinoma.
    BMC Cancer. 2019;19:34.
    PubMed     Abstract available


  336. KIM R, Keam B, Kim S, Kim M, et al
    Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    BMC Cancer. 2019;19:19.
    PubMed     Abstract available


  337. WU Z, Wang Q, Wu C, Zhan T, et al
    Three-port single-intercostal versus multiple-intercostal thoracoscopic lobectomy for the treatment of lung cancer: a propensity-matched analysis.
    BMC Cancer. 2019;19:8.
    PubMed     Abstract available


  338. WERUTSKY G, Hochhegger B, Lopes de Figueiredo Pinto JA, Martinez-Mesa J, et al
    PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114).
    BMC Cancer. 2019;19:5.
    PubMed     Abstract available


    December 2018
  339. GUO HQ, Jia J, Zhao LL, Zhao H, et al
    Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2018;18:1277.
    PubMed     Abstract available


  340. REMEN T, Pintos J, Abrahamowicz M, Siemiatycki J, et al
    Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal.
    BMC Cancer. 2018;18:1275.
    PubMed     Abstract available


  341. SUN H, Gao D
    Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372.
    BMC Cancer. 2018;18:1252.
    PubMed     Abstract available


  342. YOSHIMURA A, Yamada T, Okura N, Takeda T, et al
    The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1241.
    PubMed     Abstract available


  343. TSUTANI Y, Miyata Y, Masuda T, Fujitaka K, et al
    Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    BMC Cancer. 2018;18:1231.
    PubMed     Abstract available


  344. NG KEE KWONG F, Nicholson AG, Pavlidis S, Adcock IM, et al
    PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
    BMC Cancer. 2018;18:1238.
    PubMed     Abstract available


  345. HUANG Y, Wei S, Jiang N, Zhang L, et al
    The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:1235.
    PubMed     Abstract available


  346. LEE JS, Hur JY, Kim IA, Kim HJ, et al
    Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    BMC Cancer. 2018;18:1236.
    PubMed     Abstract available


  347. KIM EY, Kim A, Lee G, Lee H, et al
    Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma.
    BMC Cancer. 2018;18:1221.
    PubMed     Abstract available


  348. TAN WL, Ng QS, Lim C, Tan EH, et al
    Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1198.
    PubMed     Abstract available


    November 2018
  349. SINGH AK, Hennon M, Ma SJ, Demmy TL, et al
    A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.
    BMC Cancer. 2018;18:1183.
    PubMed     Abstract available


  350. SCHWARTZ RM, Lieberman-Cribbin W, Wolf A, Flores RM, et al
    Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.
    BMC Cancer. 2018;18:1188.
    PubMed     Abstract available


  351. LIU K, Xu SH, Chen Z, Zeng QX, et al
    TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes of lung cancer through modulation of the Hsp90alpha/uPA/MMP2 signaling pathway.
    BMC Cancer. 2018;18:1167.
    PubMed     Abstract available


  352. CHEN RL, Zhao J, Zhang XC, Lou NN, et al
    Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    BMC Cancer. 2018;18:1171.
    PubMed     Abstract available


  353. DE MOL M, Visser S, Aerts JGJV, Lodder P, et al
    Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of life-BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients
    BMC Cancer. 2018;18:1173.
    PubMed     Abstract available


  354. VOLLBRECHT C, Lenze D, Hummel M, Lehmann A, et al
    RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    BMC Cancer. 2018;18:1158.
    PubMed     Abstract available


  355. RICH A, Baldwin D, Alfageme I, Beckett P, et al
    Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries.
    BMC Cancer. 2018;18:1144.
    PubMed     Abstract available


  356. JIN B, Zhang S, Chuang X, Yu P, et al
    Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.
    BMC Cancer. 2018;18:1138.
    PubMed     Abstract available


  357. YOSHIDA R, Sasaki T, Umekage Y, Tanno S, et al
    Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR.
    BMC Cancer. 2018;18:1136.
    PubMed     Abstract available


  358. ZANELLI M, Mengoli MC, Del Sordo R, Cagini A, et al
    Intravascular NK/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: a clinical dilemma.
    BMC Cancer. 2018;18:1115.
    PubMed     Abstract available


  359. SEIGNEURIN A, Delafosse P, Tretarre B, Woronoff AS, et al
    Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.
    BMC Cancer. 2018;18:1091.
    PubMed     Abstract available


  360. KIM EJ, Ock M, Kim KP, Jung NH, et al
    Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea.
    BMC Cancer. 2018;18:1081.
    PubMed     Abstract available


  361. PU X, Wu L, Su D, Mao W, et al
    Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
    BMC Cancer. 2018;18:1082.
    PubMed     Abstract available


  362. WANG X, Yin C, Su S, Li X, et al
    Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.
    BMC Cancer. 2018;18:1067.
    PubMed     Abstract available


  363. ZHENG LP, Chen LY, Liao XY, Xu ZH, et al
    Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
    BMC Cancer. 2018;18:1070.
    PubMed     Abstract available


    October 2018
  364. YI YS, Ban WH, Sohng KY
    Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
    BMC Cancer. 2018;18:1053.
    PubMed     Abstract available


  365. IEZZI A, Caiola E, Scagliotti A, Broggini M, et al
    Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells.
    BMC Cancer. 2018;18:1028.
    PubMed     Abstract available


  366. ZHOU F, Ma W, Li W, Ni H, et al
    Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    BMC Cancer. 2018;18:1033.
    PubMed     Abstract available


  367. SCHERPEREEL A, Durand-Zaleski I, Cotte FE, Fernandes J, et al
    Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.
    BMC Cancer. 2018;18:1013.
    PubMed     Abstract available


  368. AIKO N, Shimokawa T, Miyazaki K, Misumi Y, et al
    Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1012.
    PubMed     Abstract available


  369. LAVACCHI D, Nobili S, Brugia M, Paderi A, et al
    A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.
    BMC Cancer. 2018;18:1024.
    PubMed     Abstract available


  370. HAI Y, Chen N, Wu W, Wang Z, et al
    High postoperative monocyte indicates inferior Clinicopathological characteristics and worse prognosis in lung adenocarcinoma or squamous cell carcinoma after lobectomy.
    BMC Cancer. 2018;18:1011.
    PubMed     Abstract available


  371. GUO Y, Wang X, Xiao J, Xu Y, et al
    Lung squamous cell carcinoma with solitary ocular metastasis and its successful treatment with thoracic surgery and chemotherapy: an interesting and rare case report.
    BMC Cancer. 2018;18:1004.
    PubMed     Abstract available


  372. XU J, Guo W, Xie L
    Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
    BMC Cancer. 2018;18:987.
    PubMed     Abstract available


  373. KIM MK, Yee J, Cho YS, Jang HW, et al
    Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
    BMC Cancer. 2018;18:988.
    PubMed     Abstract available


  374. LIU L, Shi M, Wang Z, Lu H, et al
    A molecular and staging model predicts survival in patients with resected non-small cell lung cancer.
    BMC Cancer. 2018;18:966.
    PubMed     Abstract available


  375. QIN RS, Zhang ZH, Zhu NP, Chen F, et al
    Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
    BMC Cancer. 2018;18:967.
    PubMed     Abstract available


  376. WANG X, Zamdborg L, Ye H, Grills IS, et al
    A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    BMC Cancer. 2018;18:962.
    PubMed     Abstract available


  377. ISAKA T, Nakayama H, Ito H, Yokose T, et al
    Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    BMC Cancer. 2018;18:959.
    PubMed     Abstract available


  378. TACHIHARA M, Negoro S, Inoue T, Tamiya M, et al
    Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    BMC Cancer. 2018;18:946.
    PubMed     Abstract available


  379. SABATH B, Muhammad HA, Balagani A, Ost DE, et al
    Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
    BMC Cancer. 2018;18:937.
    PubMed     Abstract available


    September 2018
  380. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Engaging the older cancer patient; Patient Activation through Counseling, Exercise and Mobilization - Pancreatic, Biliary tract and Lung cancer (PACE-Mobil-PBL) - study protocol of a randomized controlled trial.
    BMC Cancer. 2018;18:934.
    PubMed     Abstract available


  381. ANDRIANI F, Landoni E, Mensah M, Facchinetti F, et al
    Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer.
    BMC Cancer. 2018;18:899.
    PubMed     Abstract available


  382. YIN Z, Cui Z, Li H, Li J, et al
    Polymorphisms in the H19 gene and the risk of lung Cancer among female never smokers in Shenyang, China.
    BMC Cancer. 2018;18:893.
    PubMed     Abstract available


  383. BENBRAHIM Z, Antonia T, Mellas N
    EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:891.
    PubMed     Abstract available


  384. VANHOVE K, Giesen P, Owokotomo OE, Mesotten L, et al
    The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer.
    BMC Cancer. 2018;18:868.
    PubMed     Abstract available


    August 2018
  385. KIM Y, Pierce CM, Robinson LA
    Impact of viral presence in tumor on gene expression in non-small cell lung cancer.
    BMC Cancer. 2018;18:843.
    PubMed     Abstract available


  386. FUMET JD, Wickre M, Jacquot JP, Bizollon MH, et al
    Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
    BMC Cancer. 2018;18:839.
    PubMed     Abstract available


  387. URUGA H, Moriguchi S, Takahashi Y, Ogawa K, et al
    Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
    BMC Cancer. 2018;18:825.
    PubMed     Abstract available


  388. VAUGHN CP, Costa JL, Feilotter HE, Petraroli R, et al
    Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.
    BMC Cancer. 2018;18:828.
    PubMed     Abstract available


  389. KIM MC, Hwang SH, Kim NY, Lee HS, et al
    Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.
    BMC Cancer. 2018;18:819.
    PubMed     Abstract available


  390. XU F, Ren X, Chen Y, Li Q, et al
    Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
    BMC Cancer. 2018;18:808.
    PubMed     Abstract available


  391. HUANG H, Tong TT, Yau LF, Chen CY, et al
    LC-MS based sphingolipidomic study on A549 human lung adenocarcinoma cell line and its taxol-resistant strain.
    BMC Cancer. 2018;18:799.
    PubMed     Abstract available


  392. KORDOWSKI F, Kolarova J, Schafmayer C, Buch S, et al
    Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.
    BMC Cancer. 2018;18:796.
    PubMed     Abstract available


  393. ZHANG W, Wei Y, Yu D, Xu J, et al
    Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2018;18:780.
    PubMed     Abstract available


    July 2018
  394. KIM IA, Lee JS, Kim HJ, Kim WS, et al
    Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
    BMC Cancer. 2018;18:768.
    PubMed     Abstract available


  395. SAHIN IH, Elias H, Chou JF, Capanu M, et al
    Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.
    BMC Cancer. 2018;18:769.
    PubMed     Abstract available


  396. BORM KJ, Oechsner M, Wiegandt M, Hofmeister A, et al
    Moving targets in 4D-CTs versus MIP and AIP: comparison of patients data to phantom data.
    BMC Cancer. 2018;18:760.
    PubMed     Abstract available


  397. BUTCHER K, Kannappan V, Kilari RS, Morris MR, et al
    Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line.
    BMC Cancer. 2018;18:753.
    PubMed     Abstract available


  398. MAZZA D, Lin X, Walter FM, Young JM, et al
    The LEAD study protocol: a mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds.
    BMC Cancer. 2018;18:754.
    PubMed     Abstract available


  399. BERG J, Halvorsen AR, Bengtson MB, Tasken KA, et al
    Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.
    BMC Cancer. 2018;18:739.
    PubMed     Abstract available


  400. ZACHARIAS M, Brcic L, Eidenhammer S, Popper H, et al
    Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated.
    BMC Cancer. 2018;18:717.
    PubMed     Abstract available


  401. SHENG Y, Xu M, Li C, Xiong Y, et al
    Nm23-H1 is involved in the repair of ionizing radiation-induced DNA double-strand breaks in the A549 lung cancer cell line.
    BMC Cancer. 2018;18:710.
    PubMed     Abstract available


    June 2018
  402. WANG Y, Qu X, Kam NW, Wang K, et al
    An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy.
    BMC Cancer. 2018;18:692.
    PubMed     Abstract available


  403. LI X, Zhou Q, Wang X, Su S, et al
    The effect of low insurance reimbursement on quality of care for non-small cell lung cancer in China: a comprehensive study covering diagnosis, treatment, and outcomes.
    BMC Cancer. 2018;18:683.
    PubMed     Abstract available


  404. TIAN X, Ma J, Wang T, Tian J, et al
    Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer.
    BMC Cancer. 2018;18:660.
    PubMed     Abstract available


  405. HOU X, Gong R, Zhan J, Zhou T, et al
    p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:641.
    PubMed     Abstract available


  406. ZHU H, Zhang S
    Body mass index and lung cancer risk in never smokers: a meta-analysis.
    BMC Cancer. 2018;18:635.
    PubMed     Abstract available


    May 2018
  407. MARINGE C, Pashayan N, Rubio FJ, Ploubidis G, et al
    Trends in lung cancer emergency presentation in England, 2006-2013: is there a pattern by general practice?
    BMC Cancer. 2018;18:615.
    PubMed     Abstract available


  408. SHINOZAKI T, Iwami E, Ikemura S, Matsuzaki T, et al
    A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.
    BMC Cancer. 2018;18:620.
    PubMed     Abstract available


  409. ZENG J, Zhang H, Tan Y, Sun C, et al
    Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:611.
    PubMed     Abstract available


  410. ZHENG J, Jia L, Mori S, Kodama T, et al
    Evaluation of metastatic niches in distant organs after surgical removal of tumor-bearing lymph nodes.
    BMC Cancer. 2018;18:608.
    PubMed     Abstract available


  411. WEI X, Zhang K, Qin H, Zhu J, et al
    GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma.
    BMC Cancer. 2018;18:600.
    PubMed     Abstract available


  412. MARKOCZY Z, Sarosi V, Kudaba I, Galffy G, et al
    Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
    BMC Cancer. 2018;18:598.
    PubMed     Abstract available


  413. LI H, Huang N, Zhu W, Wu J, et al
    Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
    BMC Cancer. 2018;18:579.
    PubMed     Abstract available


  414. ZHOU W, Chen X, Hu Q, Chen X, et al
    Galectin-3 activates TLR4/NF-kappaB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.
    BMC Cancer. 2018;18:580.
    PubMed     Abstract available


  415. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Abstract available


  416. LIMVIPHUVADH V, Tan CS, Konishi F, Jenjaroenpun P, et al
    Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.
    BMC Cancer. 2018;18:555.
    PubMed     Abstract available


  417. LI Y, Chen G, Chen H, Wen S, et al
    Spontaneous renal hemorrhage secondary to choriocarcinoma in a man with congenital hypospadias and cryptorchidism: a case report and literature review.
    BMC Cancer. 2018;18:543.
    PubMed     Abstract available


  418. EZZELDIN N, El-Lebedy D, Darwish A, El Bastawisy A, et al
    Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.
    BMC Cancer. 2018;18:525.
    PubMed     Abstract available


  419. QUAIFE SL, Vrinten C, Ruparel M, Janes SM, et al
    Smokers' interest in a lung cancer screening programme: a national survey in England.
    BMC Cancer. 2018;18:497.
    PubMed     Abstract available


  420. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Abstract available


    April 2018
  421. BLUM W, Pecze L, Rodriguez JW, Steinauer M, et al
    Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter.
    BMC Cancer. 2018;18:475.
    PubMed     Abstract available


  422. MORRISON BJ, Steel JC, Morris JC
    Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    BMC Cancer. 2018;18:469.
    PubMed     Abstract available


  423. HE F, Xiao RD, Lin T, Xiong WM, et al
    Dietary patterns, BCMO1 polymorphisms, and primary lung cancer risk in a Han Chinese population: a case-control study in Southeast China.
    BMC Cancer. 2018;18:445.
    PubMed     Abstract available


  424. MISHRA DK, Miller RA, Pence KA, Kim MP, et al
    Small cell and non small cell lung cancer form metastasis on cellular 4D lung model.
    BMC Cancer. 2018;18:441.
    PubMed     Abstract available


  425. GIGER-PABST U, Demtroder C, Falkenstein TA, Ouaissi M, et al
    Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.
    BMC Cancer. 2018;18:442.
    PubMed     Abstract available


  426. ABBAS HHK, Alhamoudi KMH, Evans MD, Jones GDD, et al
    MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    BMC Cancer. 2018;18:423.
    PubMed     Abstract available


  427. DHONT L, Pintilie M, Kaufman E, Navab R, et al
    Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).
    BMC Cancer. 2018;18:429.
    PubMed     Abstract available


  428. AI X, Mao F, Shen S, Shentu Y, et al
    Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.
    BMC Cancer. 2018;18:407.
    PubMed     Abstract available


  429. HE W, Zhang H, Wang Y, Zhou Y, et al
    CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9.
    BMC Cancer. 2018;18:400.
    PubMed     Abstract available


  430. VANNIMENUS C, Bricout H, Le Rouzic O, Mouawad F, et al
    Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study.
    BMC Cancer. 2018;18:372.
    PubMed     Abstract available


  431. THRIUMANI R, Zakaria A, Hashim YZH, Jeffree AI, et al
    A study on volatile organic compounds emitted by in-vitro lung cancer cultured cells using gas sensor array and SPME-GCMS.
    BMC Cancer. 2018;18:362.
    PubMed     Abstract available


    March 2018
  432. TAN PT, Aziz MIA, Pearce F, Lim WT, et al
    Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    BMC Cancer. 2018;18:352.
    PubMed     Abstract available


  433. BRUECKL WM, Achenbach HJ, Ficker JH, Schuette W, et al
    Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    BMC Cancer. 2018;18:333.
    PubMed     Abstract available


  434. NAGAMATSU Y, Oze I, Aoe K, Hotta K, et al
    Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
    BMC Cancer. 2018;18:350.
    PubMed     Abstract available


  435. WANG Y, Zhang S, Wu F, Zhao J, et al
    Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
    BMC Cancer. 2018;18:326.
    PubMed     Abstract available


  436. MAMBETSARIEV I, Vora L, Yu KW, Salgia R, et al
    Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
    BMC Cancer. 2018;18:314.
    PubMed     Abstract available


  437. FIDLER MJ, Fhied CL, Roder J, Basu S, et al
    The serum-based VeriStrat(R) test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
    BMC Cancer. 2018;18:310.
    PubMed     Abstract available


  438. LYNCH JA, Berse B, Rabb M, Mosquin P, et al
    Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
    BMC Cancer. 2018;18:306.
    PubMed     Abstract available


  439. HAKOZAKI T, Okuma Y, Kashima J
    Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.
    BMC Cancer. 2018;18:302.
    PubMed     Abstract available


  440. BRIZZI MP, La Salvia A, Tampellini M, Sonetto C, et al
    Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.
    BMC Cancer. 2018;18:311.
    PubMed     Abstract available


  441. YORITA K, Tsuji K, Takano Y, Kuroda N, et al
    Acantholytic squamous cell carcinoma of the lung with marked lymphogenous metastases and high titers of myeloperoxidase-antineutrophil cytoplasmic antibodies: a case report.
    BMC Cancer. 2018;18:300.
    PubMed     Abstract available


  442. TAI LH, Ananth AA, Seth R, Alkayyal A, et al
    Sepsis increases perioperative metastases in a murine model.
    BMC Cancer. 2018;18:277.
    PubMed     Abstract available


  443. YAO D, Zhang L, Wu PL, Gu XL, et al
    Clinical and misdiagnosed analysis of primary pulmonary lymphoma: a retrospective study.
    BMC Cancer. 2018;18:281.
    PubMed     Abstract available


  444. RYSKA A, Berzinec P, Brcic L, Cufer T, et al
    NSCLC molecular testing in Central and Eastern European countries.
    BMC Cancer. 2018;18:269.
    PubMed     Abstract available


  445. WANG G, Guo C, Zhao H, Pan Z, et al
    TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location.
    BMC Cancer. 2018;18:260.
    PubMed     Abstract available


  446. JIN BF, Yang F, Ying XM, Gong L, et al
    Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
    BMC Cancer. 2018;18:259.
    PubMed     Abstract available


  447. LEE DW, Lee KH, Kim HJ, Kim TY, et al
    A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
    BMC Cancer. 2018;18:252.
    PubMed     Abstract available


  448. IKEDA S, Kato T, Ogura T, Sekine A, et al
    Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thorac
    BMC Cancer. 2018;18:241.
    PubMed     Abstract available


    February 2018
  449. BROGDEN KA, Parashar D, Hallier AR, Braun T, et al
    Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    BMC Cancer. 2018;18:225.
    PubMed     Abstract available


  450. SANIKINI H, Yuan JM, Butler LM, Koh WP, et al
    Body mass index and lung cancer risk: a pooled analysis based on nested case-control studies from four cohort studies.
    BMC Cancer. 2018;18:220.
    PubMed     Abstract available


  451. DE FONSEKA D, Arnold DT, Stadon L, Morley A, et al
    A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
    BMC Cancer. 2018;18:199.
    PubMed     Abstract available


  452. DEMUTH C, Madsen AT, Weber B, Wu L, et al
    The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    BMC Cancer. 2018;18:191.
    PubMed     Abstract available


  453. CHU GCW, Lazare K, Sullivan F
    Serum and blood based biomarkers for lung cancer screening: a systematic review.
    BMC Cancer. 2018;18:181.
    PubMed     Abstract available


  454. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Abstract available


  455. OLIVIER C, Grosbois JM, Cortot AB, Peres S, et al
    Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.
    BMC Cancer. 2018;18:178.
    PubMed     Abstract available


  456. MERVAI Z, Egedi K, Kovalszky I, Baghy K, et al
    Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.
    BMC Cancer. 2018;18:157.
    PubMed     Abstract available


  457. WANG ZF, Ren SX, Li W, Gao GH, et al
    Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:148.
    PubMed     Abstract available


  458. SCHUETTE W, Schirmacher P, Eberhardt WEE, Dietel M, et al
    Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    BMC Cancer. 2018;18:135.
    PubMed     Abstract available


    January 2018
  459. OU JY, Fowler B, Ding Q, Kirchhoff AC, et al
    A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population.
    BMC Cancer. 2018;18:115.
    PubMed     Abstract available


  460. ARRIOLA E, Garcia Gomez R, Diz P, Majem M, et al
    Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    BMC Cancer. 2018;18:106.
    PubMed     Abstract available


  461. NARUMI Y, Yoshida R, Minami Y, Yamamoto Y, et al
    Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
    BMC Cancer. 2018;18:95.
    PubMed     Abstract available


  462. MOKHLES S, Nuyttens JJME, de Mol M, Aerts JGJV, et al
    Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making.
    BMC Cancer. 2018;18:79.
    PubMed     Abstract available


  463. WU N, Ren D, Li S, Ma W, et al
    RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.
    BMC Cancer. 2018;18:67.
    PubMed     Abstract available


  464. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Abstract available


  465. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Abstract available


  466. QU TT, Chen F, Wang J, Zhang YJ, et al
    PCAF-mediated acetylation of Lin28B increases let-7 biogenesis in lung adenocarcinoma H1299 cells.
    BMC Cancer. 2018;18:27.
    PubMed     Abstract available


  467. ZHOU J, Zheng J, Zhang X, Zhao J, et al
    Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    BMC Cancer. 2018;18:10.
    PubMed     Abstract available


  468. KANEDA T, Yoshioka H, Tamiya M, Tamiya A, et al
    Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    BMC Cancer. 2018;18:6.
    PubMed     Abstract available


    December 2017
  469. LIU D, Huang Y, Li L, Song J, et al
    High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    BMC Cancer. 2017;17:882.
    PubMed     Abstract available


  470. WANG D, Haley JD, Thompson P
    Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages.
    BMC Cancer. 2017;17:830.
    PubMed     Abstract available


  471. BLANCO-PRIETO S, Barcia-Castro L, Paez de la Cadena M, Rodriguez-Berrocal FJ, et al
    Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis.
    BMC Cancer. 2017;17:823.
    PubMed     Abstract available


    November 2017
  472. IKEDA S, Yoshioka H, Ikeo S, Morita M, et al
    Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
    BMC Cancer. 2017;17:797.
    PubMed     Abstract available


  473. NAITO T, Okayama T, Aoyama T, Ohashi T, et al
    Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
    BMC Cancer. 2017;17:800.
    PubMed     Abstract available


  474. HIGUCHI Y, Motoki T, Ishida H, Kanamitsu K, et al
    Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
    BMC Cancer. 2017;17:775.
    PubMed     Abstract available


  475. KRISHNASWAMY S, Mohammed AK, Tripathi G, Alokail MS, et al
    Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
    BMC Cancer. 2017;17:738.
    PubMed     Abstract available


  476. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Abstract available


  477. WANG T, Chen X, Qiao W, Kong L, et al
    Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer.
    BMC Cancer. 2017;17:719.
    PubMed     Abstract available


    October 2017
  478. TANAKA H, Taima K, Morimoto T, Tanaka Y, et al
    A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
    BMC Cancer. 2017;17:683.
    PubMed     Abstract available


    September 2017
  479. EDBROOKE L, Aranda S, Granger CL, McDonald CF, et al
    Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer - protocol for a phase II randomised controlled trial.
    BMC Cancer. 2017;17:663.
    PubMed     Abstract available


  480. JIN R, Chen X, Han D, Luo X, et al
    Clusterin modulates transdifferentiation of non-small-cell lung cancer.
    BMC Cancer. 2017;17:661.
    PubMed     Abstract available


  481. URUSHIYAMA H, Jo T, Yasunaga H, Yamauchi Y, et al
    Adjuvant chemotherapy versus chemoradiotherapy for small cell lung cancer with lymph node metastasis: a retrospective observational study with use of a national database in Japan.
    BMC Cancer. 2017;17:613.
    PubMed     Abstract available


    August 2017
  482. WANG X, Su S, Li S, Bao H, et al
    Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China.
    BMC Cancer. 2017;17:603.
    PubMed     Abstract available


  483. AARELEID T, Zimmermann ML, Baburin A, Innos K, et al
    Divergent trends in lung cancer incidence by gender, age and histological type in Estonia: a nationwide population-based study.
    BMC Cancer. 2017;17:596.
    PubMed     Abstract available


  484. PARK SM, Lee J, Kim YA, Chang YJ, et al
    Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea.
    BMC Cancer. 2017;17:600.
    PubMed     Abstract available


  485. HATA Y, Kiribayashi T, Kishi K, Nagashima M, et al
    Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
    BMC Cancer. 2017;17:581.
    PubMed     Abstract available


  486. NAITO T, Okayama T, Aoyama T, Ohashi T, et al
    Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2017;17:571.
    PubMed     Abstract available


  487. SZTANKAY M, Giesinger JM, Zabernigg A, Krempler E, et al
    Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
    BMC Cancer. 2017;17:565.
    PubMed     Abstract available


  488. LEE YS, Nam HS, Lim JH, Kim JS, et al
    Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
    BMC Cancer. 2017;17:557.
    PubMed     Abstract available


    July 2017
  489. FUGAZZARO S, Costi S, Mainini C, Kopliku B, et al
    PUREAIR protocol: randomized controlled trial of intensive pulmonary rehabilitation versus standard care in patients undergoing surgical resection for lung cancer.
    BMC Cancer. 2017;17:508.
    PubMed     Abstract available


  490. WANG Q, Cheng Y, Wang Y, Fan Y, et al
    Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    BMC Cancer. 2017;17:492.
    PubMed     Abstract available


  491. KIM EY, Jung JY, Kim A, Kim K, et al
    Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.
    BMC Cancer. 2017;17:467.
    PubMed     Abstract available


  492. ZHOU Q, Song Y, Zhang X, Chen GY, et al
    A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    BMC Cancer. 2017;17:462.
    PubMed     Abstract available


    June 2017
  493. RADWAN N, Phillips R, Ross A, Rowe SP, et al
    A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    BMC Cancer. 2017;17:453.
    PubMed     Abstract available


  494. SNEDDON S, Patch AM, Dick IM, Kazakoff S, et al
    Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
    BMC Cancer. 2017;17:396.
    PubMed     Abstract available


    May 2017
  495. JOHNEN G, Gawrych K, Raiko I, Casjens S, et al
    Calretinin as a blood-based biomarker for mesothelioma.
    BMC Cancer. 2017;17:386.
    PubMed     Abstract available


  496. MISUMI Y, Okamoto H, Sasaki J, Masuda N, et al
    Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    BMC Cancer. 2017;17:377.
    PubMed     Abstract available


  497. KULASINGHE A, Perry C, Kenny L, Warkiani ME, et al
    PD-L1 expressing circulating tumour cells in head and neck cancers.
    BMC Cancer. 2017;17:333.
    PubMed     Abstract available


  498. GAMBICHLER T, Strutzmann S, Tannapfel A, Susok L, et al
    Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
    BMC Cancer. 2017;17:327.
    PubMed     Abstract available


  499. YEO J, Crawford EL, Zhang X, Khuder S, et al
    A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.
    BMC Cancer. 2017;17:301.
    PubMed     Abstract available


  500. NAKAMURA K, Kato M, Shukuya T, Mori K, et al
    Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    BMC Cancer. 2017;17:302.
    PubMed     Abstract available


  501. SHIMAZU K, Tada Y, Morinaga T, Shingyoji M, et al
    Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
    BMC Cancer. 2017;17:309.
    PubMed     Abstract available


  502. TAYLOR SA, Mallett S, Miles A, Beare S, et al
    Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
    BMC Cancer. 2017;17:299.
    PubMed     Abstract available


    April 2017
  503. OHSAKI Y, Sasaki T, Endo S, Kitada M, et al
    Observation of Zn-photoprotoporphyrin red Autofluorescence in human bronchial cancer using color-fluorescence endoscopy.
    BMC Cancer. 2017;17:289.
    PubMed     Abstract available


  504. ZHOU T, Zhan J, Fang W, Zhao Y, et al
    Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).
    BMC Cancer. 2017;17:269.
    PubMed     Abstract available


  505. ZHAO F, Zhou Y, Ge PF, Huang CJ, et al
    A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non-small cell lung cancer.
    BMC Cancer. 2017;17:267.
    PubMed     Abstract available


  506. HORIMASU Y, Ishikawa N, Tanaka S, Hirano C, et al
    MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study.
    BMC Cancer. 2017;17:263.
    PubMed     Abstract available


  507. YANG X, Pei S, Wang H, Jin Y, et al
    Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    BMC Cancer. 2017;17:255.
    PubMed     Abstract available


  508. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Abstract available


    March 2017
  509. FRUGTNIET BA, Martin TA, Zhang L, Jiang WG, et al
    Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion.
    BMC Cancer. 2017;17:224.
    PubMed     Abstract available


  510. AK G, Tada Y, Shimada H, Metintas S, et al
    Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    BMC Cancer. 2017;17:212.
    PubMed     Abstract available


  511. BHANGOO MS, Zhou JY, Ali SM, Madison R, et al
    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
    BMC Cancer. 2017;17:197.
    PubMed     Abstract available


  512. WANG JZ, Xiang JJ, Wu LG, Bai YS, et al
    A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis.
    BMC Cancer. 2017;17:167.
    PubMed     Abstract available


    February 2017
  513. FERNANDEZ-MARTINEZ L, Villegas JA, Santamaria I, Pitiot AS, et al
    Identification of somatic and germ-line DICER1 mutations in pleuropulmonary blastoma, cystic nephroma and rhabdomyosarcoma tumors within a DICER1 syndrome pedigree.
    BMC Cancer. 2017;17:146.
    PubMed     Abstract available


  514. MA J, Yang QL, Ling Y
    Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
    BMC Cancer. 2017;17:132.
    PubMed     Abstract available


  515. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Abstract available


    January 2017
  516. WANG L, Liu D, Lu J, Zhang S, et al
    The feasibility and advantage of uniportal video-assisted thoracoscopic surgery (VATS) in pulmonary lobectomy.
    BMC Cancer. 2017;17:75.
    PubMed     Abstract available


  517. VALTCHEVA N, Lang FM, Noske A, Samartzis EP, et al
    Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    BMC Cancer. 2017;17:66.
    PubMed     Abstract available


  518. GOTO T, Hirotsu Y, Mochizuki H, Nakagomi T, et al
    Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report.
    BMC Cancer. 2017;17:65.
    PubMed     Abstract available


  519. PALSHOF JA, Hogdall EV, Poulsen TS, Linnemann D, et al
    Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
    BMC Cancer. 2017;17:48.
    PubMed     Abstract available


  520. MARRER E, Jolly D, Arveux P, Lejeune C, et al
    Incidence of solitary pulmonary nodules in Northeastern France: a population-based study in five regions.
    BMC Cancer. 2017;17:47.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: